Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors

Clinical trial NCT02930967 · UNKNOWN

Trial details

NCT number: NCT02930967
Sponsor: China Meitan General Hospital
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent PD-L1+ Malignant Tumors Metastatic PD-L1+ Malignant Tumors

Start date: 2016-08-01
Primary completion: 2018-08-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.